Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
JAMA Surgery|May 9, 2014
Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanomaCarlo Riccardo Rossi, Nicola Mozzillo, Andrea Maurichi, et al.Cancer Immunology, Immunotherapy : CII|May 15, 2015
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II studyRiccardo Danielli, Roberto Patuzzo, Anna Maria Di Giacomo, et al.Cancer Immunology, Immunotherapy : CII|April 30, 2013
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)Antonia Busse, Jérôme Rapion, Alberto Fusi, et al.European Journal of Cancer (Oxford, England : 1990)|November 8, 2011
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Alexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.Journal of Surgical Oncology|June 8, 2012
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanomaFrancesco Papadia, Valeria Basso, Roberto Patuzzo, et al.Stem Cells (Dayton, Ohio)|June 15, 2016
Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating CellsAlessandra Tuccitto, Marcella Tazzari, Valeria Beretta, et al.International Journal of Cancer|October 31, 2009
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidityAngelo De Milito, Rossella Canese, Maria Lucia Marino, et al.Lancet (London, England)|July 16, 2008
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander Mm Eggermont, Stefan Suciu, Mario Santinami, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma GroupAndrew Bottomley, Corneel Coens, Stefan Suciu, et al.Cancer Research|May 18, 2012
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytesArianna Calcinotto, Paola Filipazzi, Matteo Grioni, et al.Pageof 11